Investment
Features
FeesSafety
Academy
More
Pluang+

Compare State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF (FLRN) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETFTrade
Inovio Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF vs Inovio Pharmaceuticals Inc — how do they compare? State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF trades at $30.77, while Inovio Pharmaceuticals Inc trades at $0.8 (market cap $78.55M). The key difference: State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

FLRNINO
Sector
Sector/ThematicHealth
52-Week High
$30.86$2.87
52-Week Low
$30.65$0.66
Market Cap
$78.55M
Enterprise Value
$49.56M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF

FLRN trades at $30.77, showing minimal daily change of 0.03%. Technical indicators signal a bearish trend with moving averages and ADX pointing downward, though RSI suggests potential oversold conditions. The company has maintained consistent dividend payments of $0.11 per share through mid-2026. Key financial ratios including P/E, P/S, and ROE remain unavailable in current data.

Investment outlook remains cautious due to bearish technical signals and lack of current fundamental data. The consistent dividend provides income stability, but without updated financial metrics, assessing valuation and growth prospects is challenging. Primary risks include reliance on historical dividend patterns and potential market volatility amid inflationary pressures.

Inovio Pharmaceuticals Inc

INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.

The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF

FLRN invests in U.S. dollar-denominated investment-grade floating rate notes with maturities under five years. It provides exposure to corporate and supranational debt whose interest payments adjust with market rates, helping to mitigate interest rate risk.

Read more on FLRN

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO